Encontrados 2 documentos, a visualizar página 1 de 1
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definiti...
Aapro, MS; Van Wijk, FH; Bolis, G; Chevallier, B; Van der Burg, ME; Oliveira, CFBACKGROUND: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination. PATIENTS AND METHO...
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin i...
Wagenaar, HC; Pecorelli, S; Curran, D; Wagener, DJ; Kobierska, A; Bolis, G; Oliveira, CFOBJECTIVE: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. METHODS: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 ...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||